BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs 2016;25:709-18. [PMID: 26967267 DOI: 10.1517/13543784.2016.1165204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Yuan X, Chen Y, Tang M, Wei Y, Shi M, Yang Y, Zhou Y, Yang T, Liu J, Liu K, Deng D, Zhang C, Chen L. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs). J Med Chem 2022. [PMID: 35709396 DOI: 10.1021/acs.jmedchem.2c00604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Wang X, Chen S, Xiang H, Liang Z, Lu H. Role of sphingosine-1-phosphate receptors in vascular injury of inflammatory bowel disease. J Cell Mol Med 2021;25:2740-9. [PMID: 33595873 DOI: 10.1111/jcmm.16333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel Dis 2021;27:1674-83. [PMID: 33295611 DOI: 10.1093/ibd/izaa318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhou XL, Yang J, Qu XJ, Meng J, Miao RR, Cui SX. M10, a Myricetin-3-O-b-D-Lactose Sodium Salt, Prevents Ulcerative Colitis Through Inhibiting Necroptosis in Mice. Front Pharmacol 2020;11:557312. [PMID: 33041798 DOI: 10.3389/fphar.2020.557312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Leonard KA, Madge LA, Krawczuk PJ, Wang A, Kreutter KD, Bacani GM, Chai W, Smith RC, Tichenor MS, Harris MC, Malaviya R, Seierstad M, Johnson ME, Venable JD, Kim S, Hirst GC, Mathur AS, Rao TS, Edwards JP, Rizzolio MC, Koudriakova T. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem 2020;63:2915-29. [DOI: 10.1021/acs.jmedchem.9b01439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
6 Zhao M, Bendtsen F, Petersen AM, Larsen L, Dige A, Hvas C, Seidelin JB, Burisch J. Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open 2020;10:e035756. [PMID: 32102828 DOI: 10.1136/bmjopen-2019-035756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sun M, Zhou Y, Shi Y, Liu B. Effect of the Sphingosine Kinase 1 Selective Inhibitor, PF543 on Dextran Sodium Sulfate-Induced Colitis in Mice. DNA Cell Biol 2019;38:1338-45. [PMID: 31464523 DOI: 10.1089/dna.2019.4737] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Panés J, Gisbert JP. Efficacy of tofacitinib treatment in ulcerative colitis. Gastroenterología y Hepatología (English Edition) 2019;42:403-412. [DOI: 10.1016/j.gastre.2019.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Panés J, Gisbert JP. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2019;42:403-12. [DOI: 10.1016/j.gastrohep.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
10 Pabari RM, Mattu C, Partheeban S, Almarhoon A, Boffito M, Ciardelli G, Ramtoola Z. Novel polyurethane-based nanoparticles of infliximab to reduce inflammation in an in-vitro intestinal epithelial barrier model. Int J Pharm 2019;565:533-42. [PMID: 31085256 DOI: 10.1016/j.ijpharm.2019.05.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
11 Serra López-matencio JM, Morell Baladrón A, Castañeda S. JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina Clínica (English Edition) 2019;152:353-60. [DOI: 10.1016/j.medcle.2019.02.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Serra López-matencio JM, Morell Baladrón A, Castañeda S. Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina Clínica 2019;152:353-60. [DOI: 10.1016/j.medcli.2018.10.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gentili M, Ronchetti S, Ricci E, Di Paola R, Gugliandolo E, Cuzzocrea S, Bereshchenko O, Migliorati G, Riccardi C. Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease. Pharmacol Res 2019;141:21-31. [PMID: 30552973 DOI: 10.1016/j.phrs.2018.12.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
14 Tayebati SK. Phospholipid and Lipid Derivatives as Potential Neuroprotective Compounds. Molecules 2018;23:E2257. [PMID: 30189584 DOI: 10.3390/molecules23092257] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
15 Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018;192:100-111. [PMID: 30048708 DOI: 10.1016/j.pharmthera.2018.07.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 13.8] [Reference Citation Analysis]
16 Velayos F. Novel Agents in Inflammatory Bowel Disease. Treatment of Inflammatory Bowel Disease with Biologics 2018. [DOI: 10.1007/978-3-319-60276-9_17] [Reference Citation Analysis]
17 Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
18 Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77:521-546. [PMID: 28255960 DOI: 10.1007/s40265-017-0701-9] [Cited by in Crossref: 411] [Cited by in F6Publishing: 442] [Article Influence: 82.2] [Reference Citation Analysis]
19 Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16:495-503. [PMID: 28279838 DOI: 10.1016/j.autrev.2017.03.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 16.2] [Reference Citation Analysis]
20 Olivera P, Danese S, Peyrin-biroulet L. JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:693-703. [DOI: 10.1080/1744666x.2017.1291342] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
21 Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [PMID: 27856614 DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 87] [Cited by in F6Publishing: 67] [Article Influence: 17.4] [Reference Citation Analysis]